PharmaShots - Incisive news in 3 shots

@Pharmashot

Real-time summarized News in 3 shots from pharma, biotech, medtech, digital health and life sciences industry readable in 60 seconds

Noida, Uttar Pradesh, India

Joined July 2018

4KFollowing

2KFollowers

Pinned

PharmaShots - Incisive news in 3 shots@Pharmashot · Sep 23

Interested in the latest in AI and digitalization in pharma? Join industry leaders at AUTOMA+ 2024 in Zurich on Nov 18-19 to discuss cutting-edge solutions and technologies! Learn about digital transformation, AI in pharma, digital manufacturing. register👉sh.bgs.group/1ty

Pharmashot's tweet image. Interested in the latest in AI and digitalization in pharma? Join industry leaders at AUTOMA+ 2024 in Zurich on Nov 18-19 to discuss cutting-edge solutions and technologies! Learn about digital transformation, AI in pharma, digital manufacturing. register👉sh.bgs.group/1ty

962

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 25

Minnesota Medical Technologies Secures the US FDA’s 510(k) Clearance for StaySure to Manage Fecal Incontinence #mmt #staysure #fecalincontinence #usfda #510kclearance #medtech pharmashots.com/26448/minnesot…

Pharmashot's tweet card. Shots: Minnesota Medical Technologies has reported the US FDA’s 510(k) clearance to StaySure for the management of fecal incontinence (FI) A completed clinical trial demonstrated the device’s safety...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 25

Elanco’s Zenrelia Obtains the EC’s Approval to Treat Allergy and Atopic Dermatitis in Dogs #elanco #zenrelia #ilunocitinib #allergicdermatitis #atopicdermatitis #cvmp #caninehealth #animalhealth pharmashots.com/26433/elancos-…

Pharmashot's tweet card. Shots: The EC has approved Zenrelia (ilunocitinib) for the treatment of pruritus linked to allergic dermatitis & clinical symptoms of atopic dermatitis in dogs (≥12mos.) As part of the EU approval...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 25

Exelixis and Ipsen Receive the US FDA’s Approval for Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors (NETs) #exelixis #ipsen #cabometyx #cabozantinib #xl184 #ec #approval #piii #cabinet #pnet #epnet #nets #esmo2024 #nejm #regulatory pharmashots.com/26429/exelixis…

Pharmashot's tweet card. Shots: The EC has approved Cabometyx for inoperable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET) & extra-pancreatic NET (epNET) pts, who progressed on ≥1 prior systemic...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 25

Eli Lilly and Company Enters a ~$856M Deal with Gate Bioscience to Develop Molecular Gate Therapeutics #gatebioscience #elililly #moleculargate #moleculargatedrugdiscoveryengine #lillyexplorandd #lillycatalyze360 #pharma pharmashots.com/26424/eli-lill…

Pharmashot's tweet card. Shots: Eli Lilly has entered into a collaboration & license agreement with Gate Bioscience to identify, develop, & commercialize molecular gate drugs, leveraging Gate’s molecular gate drug discovery...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 25

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Various Inflammatory Diseases #matchpointtherapeutics #novartis #advancedcovalentexplorationplatform #covalentinhibitors #inflammatorydiseases #pharma pharmashots.com/26415/matchpoi…

Pharmashot's tweet card. Shots: Matchpoint & Novartis have entered into an exclusive option & license agreement to develop & commercialize oral covalent inhibitors targeting a transcription factor in inflammatory diseases...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 25

GSK’s Blenrep (Belantamab Mafodotin) Regimens Secure the EC’s Approval to Treat R/R Multiple Myeloma #gsk #blenrep #belantamabmafodotin #gsk2857916 #ec #approval #multiplemyeloma #dreamm7 #dreamm8 #darzalex #velcade #piii #regulatory pharmashots.com/26411/gsks-ble…

Pharmashot's tweet card. Shots:The EC has approved Blenrep + BorDex & PomDex in MM pts with ≥1 prior therapy. Review ongoing in the US (PDUFA: Jul 23, 2025) & China (priority review for DREAMM-7)Approval was based on P-III...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 24

LEO Pharma’s Anzupgo (Delgocitinib) Obtains the US FDA’s Approval to Treat Chronic Hand Eczema (CHE) #leopharma #anzupgo #delgocitinib #usfda #approval #chronichandeczema #piii #delta1 #delta2 #regulatory pharmashots.com/26363/leo-phar…

Pharmashot's tweet card. Shots:The US FDA has approved Anzupgo cream (delgocitinib) for treating mod. to sev. chronic hand eczema (CHE) in adults, who had inadequate response or are unamenable to topical corticosteroidsApp...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 24

Apnimed Reveals Topline P-III (LunAIRo) Trial Data of AD109 for Obstructive Sleep Apnea (OSA) #apnimed #ad109 #obstructivesleepapnea #piii #lunairo #cpaptherapy #clinicaltrial pharmashots.com/26329/apnimed-…

Pharmashot's tweet card. Shots:The P-III (LunAIRo) trial assessed AD109 (aroxybutynin 2.5mg/atomoxetine 75mg; n=329) vs PBO (n=331) for 12mos. in 660 adults with mild to sev. OSA across all weight classes, who are intolerant...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 24

Kling Biotherapeutics Partners with Sanofi to Identify Neutralizing Antibodies #klingbio #sanofi #neutralizingantibodies #klingselectplatform #monoclonalantibodies #pharma pharmashots.com/26322/kling-bi…

Pharmashot's tweet card. Shots:Kling Bio has entered into a collaboration & license option agreement with Sanofi to discover antibodies & epitopes leveraging Kling Bio’s Kling-Select platformCollaboration aims to discover &...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 24

AstraZeneca Reveals P-III (PREVAIL) Trial Data of Gefurulimab for Generalised Myasthenia Gravis (gMG) #astrazeneca #gefurulimab #piii #generalisedmyastheniagravis #prevail #nanobody #c5inhibitor #mgadl #clinicaltrial pharmashots.com/26320/astrazen…

Pharmashot's tweet card. Shots:AstraZeneca has reported P-III (PREVAIL) trial assessing gefurulimab vs PBO in 260 gMG adults for 26wks. across North America, EU, & APAC region; eligible pts could then enter an ongoing OLE...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 24

Health Canada Approves GSK’s Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma #gsk #blenrep #healthcanada #multiplemyeloma #dreamm7 #dreamm8 #darzalex #velcade #piii #regulatory pharmashots.com/26318/gsk-rece…

Pharmashot's tweet card. Shots:Health Canada has approved Blenrep + BorDex & PomDex in MM pts with ≥1 prior therapyApproval was based on P-III (DREAMM-7 & DREAMM-8) trials assessing Blenrep + BorDex vs Darzalex + BorDex in...

120

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 24

Johnson & Johnson’s Darzalex Secures the EC's Approval for High-Risk Smouldering Multiple Myeloma #janssen #johnsonandjohnson #ec #regulatory #smoulderingmultiplemyeloma #smm #piii #aquila #ema pharmashots.com/26316/johnson-…

Pharmashot's tweet card. Shots:The EC has approved Darzalex SC (daratumumab) for the treatment of adults with high‑risk smouldering multiple myeloma (SMM)Approval was based on the P-III (AQUILA) study data assessing Darzalex...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 23

Johnson & Johnson’s Imbruvica Secures the EC’s Approval for Previously Untreated Mantle Cell Lymphoma (MCL) #jnj #imbruvica #ibrutinib #mantlecelllymphoma #piii #triangle #asct #regulatory pharmashots.com/26304/johnson-…

Pharmashot's tweet card. Shots:The EC has approved a label extension for Imbruvica (ibrutinib) + R-CHOP alternating with R-DHAP (without ibrutinib), followed by ibrutinib monotx., for the treatment of previously untreated...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 23

Fresenius Secures the EC’s Approval for Conexxence and Bomyntra (Biosimilars, Prolia & Xgeva) #fresenius #conexxence #bomyntra #prolia #xgeva #ec #denosumab #amgen #eu #mab #antirankl #bonemetabolism #osteoclastformation #biosimilar pharmashots.com/26301/the-ec-a…

Pharmashot's tweet card. Shots:The EC has approved Conexxence & Bomyntra, biosimilar versions of Prolia & Xgeva (denosumab)Approval covers all indications of the reference products incl. osteoporosis in postmenopausal women...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 23

HMNC Brain Health and Spruce Biosciences Reports First Patient Dosing in P-II (TAMARIND) Trial of Tildacerfont for Major Depressive Disorder #hmncbrainhealth #sprucebiosciences #tildacerfont #phaseii #tamarind #majordepressivedisorder pharmashots.com/26296/hmnc-bra…

Pharmashot's tweet card. Shots:HMNC & Spruce has dosed the first pts with tildacerfont in P-II (TAMARIND) trial for the treatment of major depressive disorder (MDD)The P-II (TAMARIND) trial will assess tildacerfont vs PBO in...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 23

Slingshot AI Introduces Ash for Personalized Mental Health Support #slingshotai #ash #mentalhealth #therapy #radicalventures #forerunnerventures #a16z #felicis #menlo #digihealth pharmashots.com/26292/slingsho…

Pharmashot's tweet card. Shots:Slingshot AI has launched Ash, a personalized mental health support app, which is now available on both iOS & Android platformsSlingshot AI also secured a Series A extension funding co-led by...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 23

Roche’s Itovebi Regimen Receives the EC’s Approval for PIK3CA-mutated Breast Cancer #roche #itovebi #ibrance #fulvestrant #phaseiii #inavo120 #inavo121 #inavo122 #regulatory #pik3camutated #breastcancer pharmashots.com/26290/roches-i…

Pharmashot's tweet card. Shots:The EC has approved Itovebi + Ibrance & fulvestrant as a 1L therapy for adults with PIK3CA-mutated, ER+/HER2- locally advanced or metastatic breast cancer recurring on or within 12mos. of adj....

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 22

Concentra Biosciences Enters a Merger Agreement to Acquire iTeos Therapeutics #concentraBiosciences #iteostherapeutics #mergeragreement #merger #acquire pharmashots.com/26277/concentr…

Pharmashot's tweet card. Shots:Concentra Biosciences has entered into a definitive merger agreement to acquire iTeos TherapeuticsAs per the deal, iTeos Therapeutics’ shareholders will receive $10.047 per share in cash, along...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 22

Merck’s Keytruda Regimen Secures Health Canada’s Approval for FIGO 2014 Stage III-IVA Cervical Cancer #merck #keytruda #healthcanada #phaseIII #keynotea18 #engotcx11 #gog3047 #figo2014 #cervicalcancer #regulatory pharmashots.com/26276/mercks-k…

Pharmashot's tweet card. Shots:Health Canada has approved Keytruda + chemoradiotherapy (CRT) for the treatment of adults with FIGO 2014 Stage III-IVA cervical cancerApproval was based on P-III (KEYNOTE-A18/ ENGOT-cx11/GOG-...

PharmaShots - Incisive news in 3 shots@Pharmashot · Jul 22

Medtronic’s MiniMed 780G System Receives the European CE Mark for Automated Insulin Delivery #medtronic #minimed780g #cemark #lenny #hba1creduction #type2diabetes #type1diabetes #automatedinsulindelivery #hypoglycemia #usfda #medtech pharmashots.com/26271/medtroni…

Pharmashot's tweet card. Shots:Medtronic has received CE mark to extend label of MiniMed 780G system to pts (≥2yrs.), pregnant women & T2D pts; application is under the FDA’s review for T2D, plus US trial for use in pts...